BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the following healthcare conferences during February 2014:
Help employers find you! Check out all the jobs and post your resume.
